RET and non-small cell lung carcinoma: Clinical effectiveness of another mitotic-poisoning agent, docetaxel, was also improved in non-small-cell lung carcinoma (NSCLC) patients when used in combination with nintedanib, a non-selective inhibitor targeting all subtypes of VEGFRs, FGFRs, and PDGFRα and β, together with RET and FLT3 [302].